

DAFTAR PUSTAKA

- Ahmad, M. 2020. *Perilaku Pencegahan Kanker Serviks*. Media Sains Indonesia. Bandung.
- American Cancer Society (ACS) . *Breast Cancer Facts and Figures 2017- 2018*. Atlanta; 2017.
- Andayani, T.M., 2013, *Farmakoekonomi Prinsip dan Metodologi*, Bursa Ilmu, Yogyakarta.
- Birnbaum, H. G., Kessler, R. C., Lowe, S. W., Secnik, K., Greenberg, P. E., Leong, S. A., dan Swensen, A. R., 2005, Costs of attention deficit-hyperactivity disorder (ADHD) in the US: excess costs of persons with ADHD and their family members in 2000, *Current Medical Research and Opinion*, 21(2):195–205.
- Bloom, B. S., Bruno, D. J., Maman, D. Y., dan Jayadevappa, R., 2001, Usefulness of US cost-of-illness studies in healthcare decision making, *Pharmacoeconomics*, 19:207–213.
- Budiarto, W. dan Sugiharto, M., 2013. *Biaya Klaim Ina Cbgs dan Biaya Riil Penyakit Katastropik Rawat Inap Peserta Jamkesmas di Rumah Sakit Studi di 10 Rumah Sakit Milik Kementerian Kesehatan Januari–maret 2012*. Buletin Penelitian Sistem Kesehatan, 16 : 58- 65
- BPS, 2023, *Upah Minimum Kabupaten/Upah Minimum Provinsi di DI Yogyakarta (Rupiah), 2021-2023*, Badan Pusat Statistik Provinsi Daerah Istimewa Yogyakarta, <https://yogyakarta.bps.go.id/indicator/6/272/1/upah-minimum-kabupaten-upah-minimum-provinsi-di-di-yogyakarta.html>, diakses pada tanggal 19 Maret 2024
- Delam, H., Izanloo, S., Bazrafshan, M.R., and Eidi, A., 2020, Risk Factors for Cervical Cancer: An Epidemiological Review, *J Health Sci Surveillance Sys*, 8(3).
- Djamhari, E. A., et al., 2020, *Defisit Jaminan Kesehatan Nasional (JKN): Mengapa dan Bagaimana Mengatasinya?*, Perkumpulan PRAKARSA, Jakarta.
- Fadhilah, H. dan Sari, V. Y. P., 2019, Beban ekonomi yang ditanggung pasien dan keluarga akibat penyakit stroke: studi literatur, *BKM Journal of Community Medicine and Public Health*, 35:193-197.
- Faida, E. W., 2016, Analisa Pengaruh Faktor Usia, Status Pernikahan, dan Riwayat Keluarga Terhadap Pasien Kanker Payudara di Rumah Sakit Onkologi Surabaya, *Jurnal Manajemen Kesehatan STIKES Yayasan Dr. Soetomo*, Vol 2 No. 1:1-7.
- Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., ... Bray, F. (2013). *GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11*. Lyon, France.
- Ghosh, I., Mandal, R., Kundu, P., dan Biswas, J., 2016, Association of Genital Infections Other Than Human Papillomavirus with Pre-Invasive and Invasive Cervical Neoplasia, *Journal of Clinical and Diagnostic Research*, 10(2): XE01-XE06.
- GLOBOCAN 2018: *Estimated cancer incidence, mortality and prevalence worldwide in 2018*. International Agency for Research on Cancer Internet.

- Globocan, 2020, *Cervic Uteri*, diunduh dari <https://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf> pada 28 Desember 2023 pukul 16:44 WIB.
- Herlana, F., Nur, I. M., & Purbaningsih, W. (2017). Karakteristik Pasien Kanker Serviks berdasar atas Usia, Paritas, dan Gambaran Histopatologi di RSUD Al-Ihsan Bandung. *Bandung Meeting on Global Medicine & Health (BAMGMH)*, 1(1), 138–142. <http://proceeding.unisba.ac.id/index.php/BaMGMH/article/view/1481>
- Hyilin, H., Thrane, H., Pedersen, K., Kristiansen, I.S., Burger, E.A., 2019, The Healthcare Costs of Treating Human Papillomavirus-related Cancers in Norway, *BMC Cancer*, Vol. 19, No. 426. <https://doi.org/10.1186/s12885-019-5596-2>
- IMF, 2023, *World Economic Outlook Database, International Monetary Fund*, <https://www.imf.org/en/Publications/WEO/weo-database/2023/October>, diakses pada tanggal 19 Maret 2024.
- Jo, C., 2014, Cost-of-illness studies: concepts, scopes, and methods, *Clinical and Molecular Hepatology*, 20(4): 327–337.
- Kasyhap, N., Krishnan, N., Kaur, S., and Ghai, S., 2019, Risk Factors of Cervical Cancer: A Case-Control Study, *Asia Pac J Oncol Nurs.*, 6(3): 308–314.
- Kementerian Kesehatan Republik Indonesia, 2013, *Pedoman Penerapan Kajian Farmakoekonomi*, Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2014a, *Peraturan Menteri Kesehatan No. 27 tahun 2014 tentang Petunjuk Teknis Sistem Indonesian Case bAse Groups (INACBG)*, Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2014b, *Peraturan Menteri Kesehatan No. 28 tahun 2014 tentang Pedoman Pelaksanaan Program Jaminan Kesehatan Nasional*, Kemetrian Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI. (2015). Situasi Penyakit Kanker Indonesia. *Pusat Data Dan Informasi Kemenkes RI*, (2), 31–33.
- Kemenkes, 2018, *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Serviks*, Kementerian Kesehatan RI, Jakarta.
- Kementerian Kesehatan RI, 2023, *Panduan Penatalaksanaan Kanker Serviks*, Kementerian Kesehatan Republik Indonesia, jakarta.
- Kim, D. D., et al., 2020, Perspective and Costing in Cost-Effectiveness Analysis, *Pharmacoeconomics*, 38(10), 1135–1145, <https://doi.org/10.1007/s40273-020-00942-2>
- Kristina, S. A., Endarti, D., dan Aditama, H., 2022, Prediction of Productivity Costs Related to Cervical Cancer Mortality in Indonesia 2018, *The Malaysian Journal of Medical Sciences: MJMS*, 29(1), 138
- Mishra, G.A., Pimple, S.A., and Shastri, S.S., 2011, An Overview of Prevention and Early Detection of Cervical Cancers, *Indian J Med Paediatr Oncol.*, 32(3): 125–132.

- Murphy, E. M., Rodis, J. L., dan Mann, H. J., 2020, Three Ways to Advocate for The Economic Value of The Pharmacist in Health Care, *J Am Pharm Assoc (2003)*, 60(6):e116–e124.
- Nadjib M, Setiawan E, Putri S, Nealon J, Beucher S, Hadinegoro SR, *et al*, 2019, Economic burden of dengue in Indonesia, *PLOS Neglected Tropical Disease Journal*, 13(1)
- National Cancer Institute at the National Institutes of Health, 2021, *What Is Cervical Cancer?*, Diakses dari <https://www.cancer.gov/types/cervical> pada 10 September 2023 pukul 12.25 WIB.
- Neumann PJ, Sanders GD, Russell LB, Siegel JE, Ganiats TG. *Cost effectiveness in health and medicine. 2nd ed.* New York: Oxford University Press; 2017
- NCI, 2023b, *Cervical Cancer Treatment*, National Cancer Institute, USA, <https://www.cancer.gov/types/cervical/treatment>, diakses pada tanggal 6 Oktober 2023
- Nurlelawati, E., Devi, T. E. R., & Sumiati, I. (2018). Faktor yang Berhubungan dengan Kejadian Kanker Serviks di RS Pusat Pertamina Jakarta. *Midwife Journal*, 5(01), 8–16. <https://media.neliti.com/media/publications/234022-faktor-faktor-yang-berhubungan-dengan-ke-4c9aa2a2.pdf>
- Prasetya, D., Layyindah, A., Putri, S., Rosita, E., Nurjanah, A. I., dan Maftuchan, A., 2023, *Konsekuensi Finansial Pengobatan Kanker di Indonesia: Studi Kasus Penderita Kanker di Ibu Kota Jakarta*, Perkumpulan Prakarsa, Jakarta.
- Ries LAG, Harkins D, Krapcho M *et al.*, eds. SEER Cancer Statistics Review, 1975–2003. Baltimore, MD: National Cancer Institute, 2005:1–103.
- Setiawati, D. (2014). Human Papilloma Virus Dan Kanker Serviks. *Al-Sihah: The Public Health Science Journal*.
- Suhadi, R., 2020, *Seluk Beluk Hipertensi Peningkatan Kompetensi Klinis untuk Pelayanan Kefarmasian*, Sanata Dharma University Press, Yogyakarta
- Suwiyoga, K., Indrayathi, P. A., dan Noviyani, R., 2015, *Perbedaan Efektivitas, Toksisitas dan Kualitas Hidup Pasien Kanker Serviks Stadium II B–III Karsinoma Sel Skuamosapada Kemoterapi Bomp dan Paclitaxel Carboplatin*, Fakultas Kedokteran, Universitas Udayana, Bali
- Tarricone, R., 2006, Cost-of-illness analysis. What room in health economics?, *Health Policy*, 77:51–63.
- Tonin, F. S., Aznar-Lou, I., Pontinha, V. M., Pontarolo, R., dan Fernandez-Llimos, F., 2021, Principles of Pharmacoeconomic Analysis: The Case of Pharmacist-led Interventions, *Pharmacy Practice*, 19(1):2302.
- Trogdon, J. G., Liu, X., Reeder-Hayes, K. E., Rotter, J., Ekwueme, D. U., dan Wheeler, S. B., 2020, Productivity costs associated with metastatic breast cancer in younger, midlife, and older women, *Cancer*, 126(18), 4118-4125
- World Health Organization (WHO). (2010). *GLOBOCAN 2008: Cancer Incidence and Mortality Worldwide*

WHO, 2022, *Cervical Cancer*, World Health Organization, <https://www.who.int/newsroom/fact-sheets/detail/cervical-cancer>, diakses pada 28 September 2023.

Zhang, H. Penninger, JM. Li, Y. Zhong, N. Slutsky, AS. 2020. *Angiotensin converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med.* DOI: 10.1007/s00134-020-05985-9.